Modifying RA disease course with novel DMARDs
Treatment with disease-modifying antirheumatic drugs (DMARDs) continues to be the centre of expert recommendations for rheumatoid arthritis (RA), with particular focus on treat-to-target rather than agent-specific strategy. In an interview with MIMS Doctor, Dr Ho SO, Specialist in Rheumatology and Assistant Professor at the Chinese University of Hong Kong, provided an overview of current RA management principles and how newer therapies, including targeted synthetic DMARDs (tsDMARDs) such as Janus kinase (JAK) inhibitors, may benefit patients with active RA.

New Molecule

3 New

New Indication

10 New

New Brand

2 New

New Dosage Strength

1 New

Markings
Shape
Form
Color 1
Color 2
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in